Organic Chemical
J&J’s Rybrevant-Lazcluze Combo Demonstrates Superior Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC
Rybrevant, Lazcluze, Tagrisso, NSCLC, EGFR mutation, overall survival, Phase III MARIPOSA trial, chemotherapy-free regimen
Stoke Therapeutics Announces Global Phase 3 EMPEROR Study Design for Zorevunersen in Dravet Syndrome
Dravet syndrome, zorevunersen, Phase 3 trial, EMPEROR study, seizure reduction, cognitive improvement, regulatory alignment
FDA Postpones Opioids Advisory Committee Meeting and Cancels Kidney Drug Review
FDA, advisory committee, postponement, cancellation, opioids, kidney drug, regulatory meetings
Delaware Court Ruling Paves Way for Aurion Biotech IPO, Alcon to Appeal Decision
Aurion Biotech, Alcon Research, IPO, Delaware Court of Chancery, reverse stock split, voting proxy, Series C consent rights
Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025
Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.
Veru’s Enobosarm Reduces Lean Mass Loss in Patients Taking Wegovy for Weight Reduction
Enobosarm, Wegovy (semaglutide), Lean mass preservation, Weight loss, Sarcopenic obesity, GLP-1 receptor agonist
Aurion Biotech Presses On with IPO Plans Amid Legal Dispute with Investor Alcon
Aurion Biotech, IPO, legal dispute, Alcon, cell therapy, biotech investment
Takeda to Discontinue Uloric: A Gradual Decline of the Gout Medication
Takeda, Uloric, gout medication, discontinuation, cardiovascular risks, FDA scrutiny
Sackler Family and Purdue Pharma Agree to Enhanced $7.4 Billion Opioid Settlement
Sackler family, Purdue Pharma, opioid settlement, $7.4 billion, multistate agreement, opioid crisis, addiction treatment, recovery programs
Keytruda and Lenvima Combination Shows Mixed Results in Gastroesophageal Cancer Trial
Keytruda, Lenvima, gastroesophageal cancer, clinical trial, survival endpoints, progression-free survival, overall survival